Nanjing Leads Biolabs Co., Ltd. (FRA:0DX)
Germany · Delayed Price · Currency is EUR | Market Cap | 776.77M -40.4% |
| Revenue (ttm) | 27.48M |
| Net Income | -34.40M |
| EPS | -0.18 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150 |
| Open | 4.000 |
| Previous Close | 4.040 |
| Day's Range | 3.960 - 4.000 |
| 52-Week Range | 3.960 - 10.500 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 1, 2026 |
About Nanjing Leads Biolabs
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma; LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity; LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity. In addition, it develops LeadsBody platform,... [Read more]
News
Leads Biolabs Doses First Patient In Phase 1b/2 Opamtistomig Trial In Colorectal Cancer
(RTTNews) - Nanjing Leads Biolabs Co., Ltd. (9887.HK) said Friday it dosed the first patient in an open-label, multicenter Phase 1b/2 trial evaluating Opamtistomig, or LBL-024, in combination therapy ...
FDA Grants Fast Track Tag To Leads Biolabs' Opamtistomig In Biliary Tract Cancer
(RTTNews) - Nanjing Leads Biolabs Co., Ltd. (9887.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to opamtistomig (LBL-024), its investigational antib...
Nanjing Leads Biolabs To Present Opamtistomig Phase IIb Study At ESMO 2026
(RTTNews) - Nanjing Leads Biolabs Co., Ltd. (9887.HK), a clinical-stage biotechnology company announced that its pivotal registrational Phase IIb study of opamtistomig (LBL-024), as monotherapy for pa...
Nanjing Leads Biolabs Earnings release: H1 2026
Nanjing Leads Biolabs released its H1 2026 earnings on August 31, 2026, summarizing the period's financial results.
Nanjing Leads Biolabs Quarterly report: H1 2026
Nanjing Leads Biolabs has published its H1 2026 quarterly earnings report on August 31, 2026.
Nanjing Leads Biolabs Slides: H1 2026
Nanjing Leads Biolabs has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 31, 2026.
Nanjing Leads Biolabs Annual report: H2 2025
Nanjing Leads Biolabs has published its H2 2025 annual report on March 27, 2026.
Nanjing Leads Biolabs Earnings release: H2 2025
Nanjing Leads Biolabs released its H2 2025 earnings on March 27, 2026, summarizing the period's financial results.
Nanjing Leads Biolabs Slides: H2 2025
Nanjing Leads Biolabs has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 27, 2026.